Menu Close

Getting Paid to Try Again; Very Cool – Paul Price – Market Shadows

A life without mistakes is an impossible dream. Investing without disappointments along the way is equally unrealistic. With stocks and options bad choices typically result in losses. We like to think of Schedule-D write-offs as the tuition we pay for our stock market education program.

There is one technique that allows, what we hope are just occasional miscalculations, to be profitable ones. How can you be wrong yet still post a profits? Sell put options on stocks you think will go up.

Last January 29th I thought Quest Diagnostics (DGX) looked cheap at $58.25. The shares had touched $62 – $64 four times during the previous year. I expected that they would do so again before August 16, 2013. As of today DGX is still stick at $59.12.

Here is a customized chart I put together on Jan. 29, 2013 showing what those peak valuations looked like based on trailing 12-month P/Es at those moments in time. EPS for the four most recently reported quarters (through Sep. 30, 2012) were $4.50. At $58.25 Quest Diagnostics had a trailing P/E of around 12.9x.

DGX as of Jan. 29, 2013

DGX had other very favorable metrics beyond a modest multiple. The stock offered a good risk/reward proposition. Longer-term the looming implementation of Obamacare figured to stimulate demand for lab testing services. That remains true today.

DGX -  VL metrics

Selling an August $60 put for $4.30 per share committed me to buying 100 shares at a net cost of $55.70. If DGX were to close at $60 or higher on expiration date the put would expire worthless and my obligation to buy would disappear forever.

DGX shares up slightly since January but have not sustained that $60 level as 2013 estimates were reduced from $4.46 to $4.33 per share. Here is how the stock has performed since I sold the August $60 put. The break-even (a.k.a. ‘if put’ price) of $55.70 is highlighted with the green doubled-headed arrow.

DGX Jan. 29, 2013 - Jul. 19, 2013

With one month to go before expiration the short put is in some danger of being exercised. ‘Rolling out’ the option will lock in a decent gain while reestablishing the same put position, but with a February 22, 2013 expiration date.

‘Rolling a put’ means ‘buying to close’ (BTC) the near-term short put while simultaneously ‘selling to open’ (STO) a longer term expiration put. In this case I’m using the same $60 strike price. I think DGX will ultimately go sustainably above that level.

Extending the expiration gives DGX more time to reach or exceed the needed threshold price.

Here were the actual closing quotes of the two options involved.

DGX roll-out quotes and math for Market Shadows

After the rollout my obligation to buy is still for 100 shares of DGX at $60. I have sold to open twice since starting the trade last January. I bought to close only once.

The first sale netted me $4.30 per share. The second sale brought in an additional $2.70 per share. I collected a total of $7.00 per share even from start to finish. My overall break-even point has been reduced to $53 /share.

By selling, rather than buying, the put option we can ultimately make more in the end by not succeeding on the first try.

See the full details of Market Shadow’s Virtual Put Writing Portfolio here  http://marketshadows.com/virtual-portfolios/put-selling-virtual-portfolio/

Put Writing Portfolio - as of Jul. 19, 2013

The opinions expressed in this post are those of Market Shadows and the author, not those of the Wall Street Examiner. The Wall Street Examiner provides market commentary content for Market Shadows without compensation at this time but with the expectation of possible future consideration. The Wall Street Examiner does not participate in stock or options selection or strategy recommendations for Market Shadows and makes no representation regarding the accuracy or validity of the ideas expressed in the post. No recommendation or endorsement is intended or implied. This post is presented for informational purposes. Do all necessary due diligence before considering any investment.

Join the conversation and have a little fun at Capitalstool.com. If you are a new visitor to the Stool, please register and join in! To post your observations and charts, and snide, but good-natured, comments, click here to register. Be sure to respond to the confirmation email which is sent instantly. If not in your inbox, check your spam filter.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

RSS
Follow by Email
LinkedIn
Share

Discover more from The Wall Street Examiner

Subscribe now to keep reading and get access to the full archive.

Continue reading